ResMed Inc. Common Stock (RMD)
236.18
-21.47 (-8.33%)
ResMed Inc is a global leader in digital health and cloud-connected devices that serve individuals with sleep apnea, chronic obstructive pulmonary disease (COPD), and other chronic respiratory conditions
The company specializes in creating innovative solutions that improve the quality of life for patients through advanced technology, including ventilators, sleep therapy devices, and patient monitoring systems. By leveraging data analytics and machine learning, ResMed enhances patient engagement and treatment adherence, thereby promoting better health outcomes. The company's commitment to research and development allows it to continuously advance its portfolio, making a significant impact on the healthcare landscape.
ResMed (NYSE:RMD) Posts Better-Than-Expected Sales In Q4 But Stock Drops
Medical device company ResMed (NYSERMD) announced better-than-expected revenue in Q4 CY2024, with sales up 10.3% year on year to $1.28 billion. Its non-GAAP profit of $2.43 per share was 5.2% above analysts’ consensus estimates.
Via StockStory · January 31, 2025
What's going on in today's session: S&P500 moverschartmill.com
Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Friday.
Via Chartmill · January 31, 2025
In today's session, there are S&P500 stocks with remarkable trading volume.chartmill.com
Discover the S&P500 stocks that are experiencing unusual trading volume in today's session. Find out more about these stocks below.
Via Chartmill · January 31, 2025
Top S&P500 movers in Friday's sessionchartmill.com
Stay informed about the performance of the S&P500 index in the middle of the day on Friday. Uncover the top gainers and losers in today's session for valuable insights.
Via Chartmill · January 31, 2025
Should you consider RESMED INC (NYSE:RMD) for quality investing?chartmill.com
RESMED INC (NYSERMD) may be suited for quality investing, we'll explore why in this article.
Via Chartmill · November 29, 2024
Friday's session: gap up and gap down stock in the S&P500 indexchartmill.com
Stay updated with the S&P500 gap up and gap down stocks on Friday. Get a glimpse of the market's movement during today's session.
Via Chartmill · January 31, 2025
ResMed: Digital Health Drives Q2 Growthfool.com
ResMed reported robust earnings for the second quarter of fiscal 2025, surpassing expectations and showcasing strong growth in revenue and profitability.
Via The Motley Fool · January 30, 2025
Tech Stocks Rally, S&P 500 Flirts With Records, Gold Extends All-Time Highs: What's Driving Markets Friday?benzinga.com
Major stock indices have completed their recovery following Monday's sharp drop, buoyed by tech stocks rallying on the back of solid earnings and positive macroeconomic data. The S&P 500 index stands at 6,118 points at midday trading in New York, not far from the all-time high of 6,128 points reached last Friday.
Via Benzinga · January 31, 2025
Why Quality-Oriented Investors Should Consider NYSE:RMD.chartmill.com
Exploring RESMED INC (NYSERMD)'s quality characteristics.
Via Chartmill · November 7, 2024
ResMed, In A Buy Zone, Stays Flat After Handily Beating Earnings Viewsinvestors.com
The company easily beat earnings expectations, while sales were narrowly above.
Via Investor's Business Daily · January 30, 2025
Wall Street Remains Flat, Microsoft Eyes Heaviest Drop Since Late 2022, Gold Sets Fresh Records: What's Driving Markets Thursday?benzinga.com
Wall Street is struggling to find risk-on momentum, with major indexes stuck near the flatline at midday as investors assess the latest earnings reports from mega-cap tech stocks and weaker-than-expected U.S.
Via Benzinga · January 30, 2025
Reasonable Growth, Debt Levels, and a High ROIC Make RESMED INC (NYSE:RMD) Appealing to Quality Investors.chartmill.com
A fundamental analysis of (NYSERMD): Why Quality-Oriented Investors Should Consider NYSE:RMD.
Via Chartmill · January 28, 2025
This AppLovin Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Fridaybenzinga.com
Via Benzinga · January 10, 2025
Top Stock Reports For UnitedHealth, Costco & IBMtalkmarkets.com
Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group Inc., Costco Wholesale Corp., and International Business Machines Corp., as well as a micro-cap stock Smith-Midland Corp.
Via Talk Markets · January 3, 2025
Eli Lilly's Obesity Drug Wins Approval In Sleep Apnea; Will ResMed Dive?investors.com
Eli Lilly gained FDA approval late Friday for its weight-loss drug, Zepbound, as a treatment for obstructive sleep apnea.
Via Investor's Business Daily · December 20, 2024
This AutoZone Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Fridaybenzinga.com
Via Benzinga · December 13, 2024
ResMed Is 80 And 80: Hits 80-Plus Relative Strength Rating After Rising 80% In A Yearinvestors.com
ResMed also boasts a superb 96 EPS Rating out of 99, putting it in the top 4% of all companies for recent and long-term profit growth.
Via Investor's Business Daily · November 18, 2024
My 3 Favorite Stocks to Buy Right Nowfool.com
Here are three attractive stocks to buy that will give you a healthy mix of growth and dividends.
Via The Motley Fool · October 25, 2024
Tech Stocks Rally As Investors Await Magnificent 7 Earnings; Dollar Eyes Fourth Straight Positive Week: What's Driving Markets Friday?benzinga.com
Stocks are ending the week on a high note, with tech leading the charge as investors position ahead of next week’s pivotal earnings releases from five of the “Magnificent Seven” stocks.
Via Benzinga · October 25, 2024
Stock Market Mixed But Nasdaq Hits Record High As Tesla Leads Earnings Winners: Weekly Reviewinvestors.com
The major indexes were mixed for the week.
Via Investor's Business Daily · October 25, 2024
Sleep Apnea Device Maker ResMed Is A Durable MedTech, With Positive Fundamentals, Says Analystbenzinga.com
ResMed reports Q1 2025 adjusted EPS of $2.20, up 34%, beating estimates. Revenue reached $1.22 billion, up 11%, driven by demand growth.
Via Benzinga · October 25, 2024